Skip to main content

Table 1 Demographic data

From: Membrane diffusion- and capillary blood volume measurements are not useful as screening tools for pulmonary arterial hypertension in systemic sclerosis: a case control study

 

SScPAH+ N = 11

SScPAH- N = 13

Control N = 10

Age, yr

70.1 ± 9.6

66.2 ± 11.2

59.7 ± 6.5

Height, m

1.6 ± 0.1

1.7 ± 0.1

1.7 ± 0.1

Male/Female

0/9

0/12

2/8

Limited cutaneous SSc (%)

100

100

 

Haemoglobin, mmol/l

7.8 ± 1.2†

8.0 ± 0.6‡

8.6 ± 0.8

Raynaud's phenomenon (%)

100

92

 

Raynaud's phenomenon at PFT, years

19.2 ± 10.6*

6.6 ± 8.3

 

Autoantibodies (no.)

 

12

 

ANA

10

6

 

Anti-centromere

7

5

 

Anti-topoisomerase

0

  

Modified Rodnan skin score

14.1 ± 5.7

11.9 ± 5.9

 

Smoking status

7/3/1

6/4/2

8/2/0

Never/former/current (no.)

   

6-minute walking distance, m

326 ± 102

430 ± 127

 

SvO2, %

62.7 ± 6.6*

72.5 ± 2.0

 

HRCT fibrosis score‡

4.9 ± 3.4†

4.1 ± 3.4

 

HRCT ground glass score‡

7.1 ± 5.8†

3.1 ± 5.5

 

HRCT total fibrosis score‡

12.1 ± 6.8†

7.4 ± 8.5

 
  1. Values expressed as mean ± SD, otherwise as stated. Abbreviations: SScPAH+: systemic sclerosis associated pulmonary arterial hypertension. SScPAH-: SSc without PAH;. PFT: pulmonary function testing; ANA: anti-nucleolar antibodies.. SvO2: mixed venous oxygen saturation. * p < 0.05 for comparison of SScPAH+ with SScPAH-; † According to reference 23. ‡ According to reference 24.